Insider Selling: Diaceutics (LON:DXRX) Insider Sells £950,000 in Stock

Diaceutics PLC (LON:DXRX) insider Ryan Gerard Keeling sold 500,000 shares of Diaceutics stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of GBX 190, for a total value of £950,000.

Ryan Gerard Keeling also recently made the following trade(s):

• On Thursday, November 12th, Ryan Gerard Keeling sold 100,000 shares of Diaceutics stock. The stock was sold at an average price of GBX 190, for a total transaction of £190,000.

Diaceutics Price Performance

Shares of DXRX stock traded down GBX 1 during midday trading on Friday, reaching GBX 194. 330,586 shares of the company traded hands, compared to its average volume of 298,740. The firm’s 50 day simple moving average is GBX 188.20 and its two-hundred day simple moving average is GBX 160.85. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The firm has a market cap of £164.85 million, a PE ratio of -606.25 and a beta of 0.88. Diaceutics PLC has a 1-year low of GBX 125 and a 1-year high of GBX 210.

Diaceutics (LON:DXRX) last posted its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. On average, equities research analysts expect that Diaceutics PLC will post 1.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of GBX 215.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.